GLP-1s Appear to Protect Against Cancer

Recent research presented at the American Society of Clinical Oncology suggests GLP-1 obesity medications may be associated with reduced cancer risk across multiple tumor types, though findings remain correlative.

In analyses of more than 10,000 patients with cancer, GLP-1 use was linked to lower incidence in six of seven cancers studied, including significant reductions in breast, liver, colorectal, and non-small cell lung cancers, with lung cancer progression to stage IV declining from 22.3% to 10%.

Another analysis found a 30% lower breast cancer risk among women aged 45–80 using GLP-1s. Researchers caution retrospective limits while investigating anti-inflammatory and metabolic pathways. Read more from NPR here.